MONEYVIEW vs SHUKRAPHAR: Stock Comparison
Head-to-head financial and trading comparison between Moneyview Limited (MONEYVIEW) and Shukra Pharmaceuticals Limited (SHUKRAPHAR) in the Cross-Sector Peers sector.
MONEYVIEW
NSE: MONEYVIEWSHUKRAPHAR
NSE: SHUKRAPHARKey Metrics Comparison Table
| Metric | MONEYVIEW | SHUKRAPHAR | Edge / Winner |
|---|---|---|---|
| Current Market Price (CMP) | ₹53.88 | ₹61.80 | — |
| 1-Year Price Return | 0.0% | +49.2% | SHUKRAPHAR (49.20% higher) |
| 52-Week High | ₹53.88 | ₹62.09 | — |
| 52-Week Low | ₹53.88 | ₹41.42 | — |
| 30-Day Annualized Volatility | 15.0% | 47.35% | MONEYVIEW (Steadier) |
| 30-Day Average Daily Volume | 655,464,953 | 3,507,662 | MONEYVIEW (Higher Liquidity) |
| Statutory Cost to Trade ₹1 Lakh | ₹118.50 | ₹118.50 | Identical statutory tariff |
Frequently Asked Questions
Between MONEYVIEW and SHUKRAPHAR, which stock gave better returns over the last year?
SHUKRAPHAR has outperformed MONEYVIEW over the past 12 months with a gain of 49.2% compared to 0.0%.
Which stock is less volatile: MONEYVIEW or SHUKRAPHAR?
MONEYVIEW demonstrated lower price volatility (15.0% annualized) compared to SHUKRAPHAR (47.35%). Lower volatility generally indicates steadier price action during market downturns.
What is the statutory cost to buy ₹1,00,000 of MONEYVIEW vs SHUKRAPHAR?
Statutory exchange and government charges (STT, NSE turnover fees, SEBI fee, Stamp duty, and GST) are identical for delivery purchases of equal rupee value across both stocks, totaling approximately ₹118.50 on discount brokers offering zero delivery brokerage (like Zerodha or Dhan).
Are MONEYVIEW and SHUKRAPHAR direct sector competitors?
Yes, both companies operate within the Cross-Sector Peers sector in India and are actively tracked as sector peers by institutional and retail market participants.